M
Maria L. Carlsson
Researcher at University of Gothenburg
Publications - 78
Citations - 6373
Maria L. Carlsson is an academic researcher from University of Gothenburg. The author has contributed to research in topics: Agonist & Dopamine. The author has an hindex of 38, co-authored 74 publications receiving 6210 citations. Previous affiliations of Maria L. Carlsson include Sahlgrenska University Hospital.
Papers
More filters
Journal ArticleDOI
Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease
Maria L. Carlsson,Arvid Carlsson +1 more
TL;DR: The possibility that a deficient activity within the corticostriatal glutamatergic/aspartergic pathway may be an important pathophysiological component in schizophrenia is discussed, and that glutamatorgic agonists may be beneficial in the treatment of this disease.
Journal ArticleDOI
Interactions Between Monoamines, Glutamate, and GABA in Schizophrenia: New Evidence
Arvid Carlsson,Nicholas Waters,Susanna Holm-Waters,Joakim Tedroff,Marie Nilsson,Maria L. Carlsson +5 more
TL;DR: A precise identification of neurotransmitter aberrations in schizophrenia will probably provide clues for a better understanding of the disease and for the development of new treatment and prevention strategies.
Journal ArticleDOI
The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice
Maria L. Carlsson,Arvid Carlsson +1 more
TL;DR: It was shown that the selective non-competitive N-methyl-D-aspartate (NMDA) antagonist MK-801 caused a pronounced and dose-dependent increase in locomotion in mice pretreated with a combination of reserpine and α- methyl-para-tyrosine.
Journal ArticleDOI
Schizophrenia: A Subcortical Neurotransmitter Imbalance Syndrome?
Maria L. Carlsson,Arvid Carlsson +1 more
TL;DR: The possibility that a deficient activity within the cortico-striatal glutamatergic pathway is an important pathophysiological component in some cases of schizophrenia and that glutamatorgic agonists may prove beneficial in this disorder is discussed.
Journal ArticleDOI
Neurotransmitter interactions in schizophrenia—therapeutic implications
TL;DR: The finding in animal experimental models is the finding that it should be possible to alleviate psychotic conditions by stabilizing rather than paralyzing neurocircuits, thus avoiding the risk of motor and mental side effects of the currently used drugs.